Creative Planning’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Creative Planning’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-20,000	Closed	-$100K	–	2124
2018 Q4	$100K	Buy	+20,000	New	+$411K	﹤0.01%	1631
2017 Q3	–	Sell	-3,000	Closed	-$22K	–	4196
2017 Q2	$22K	Buy	+3,000	New	+$120K	﹤0.01%	3137

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Creative Planning's PTLA Position: Q2 2020 in Review

Creative Planning sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 187,029 shares — an estimated $1.33M sold.

Creative Planning first reported a position in PTLA in Q1 2015 and held it in 21 quarters. The position peaked at $11.4M in Q1 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

Creative Planning reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Creative Planning sold 187,029 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $1.33M.
Creative Planning first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 21 quarters.
Creative Planning's Portola Pharmaceuticals, Inc. position peaked at $11.4M in Q1 2019.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Creative Planning's 13F filing for Q2 2020, filed 23 Jul 2020.